Hvad angår hudkræfttilfældene konkluderede CHMP, at det ikke er sandsynligt, at disse er forårsaget af behandlingen med tacrolimus.
With regard to the skin cancers, the CHMP concluded that treatment with tacrolimus was not likely to have caused these skin malignancies.